JP2017108751A5 - - Google Patents

Download PDF

Info

Publication number
JP2017108751A5
JP2017108751A5 JP2017023924A JP2017023924A JP2017108751A5 JP 2017108751 A5 JP2017108751 A5 JP 2017108751A5 JP 2017023924 A JP2017023924 A JP 2017023924A JP 2017023924 A JP2017023924 A JP 2017023924A JP 2017108751 A5 JP2017108751 A5 JP 2017108751A5
Authority
JP
Japan
Prior art keywords
arg
etv5
gene
exons
tmprss2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017023924A
Other languages
English (en)
Japanese (ja)
Other versions
JP6404378B2 (ja
JP2017108751A (ja
Filing date
Publication date
Priority claimed from US11/825,552 external-priority patent/US10041123B2/en
Application filed filed Critical
Publication of JP2017108751A publication Critical patent/JP2017108751A/ja
Publication of JP2017108751A5 publication Critical patent/JP2017108751A5/ja
Application granted granted Critical
Publication of JP6404378B2 publication Critical patent/JP6404378B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017023924A 2007-07-06 2017-02-13 前立腺癌における再発性遺伝子融合 Expired - Fee Related JP6404378B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/825,552 US10041123B2 (en) 2005-09-12 2007-07-06 Recurrent gene fusions in prostate cancer
US11/825,552 2007-07-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015205414A Division JP2016019542A (ja) 2007-07-06 2015-10-19 前立腺癌における再発性遺伝子融合

Publications (3)

Publication Number Publication Date
JP2017108751A JP2017108751A (ja) 2017-06-22
JP2017108751A5 true JP2017108751A5 (enExample) 2017-11-30
JP6404378B2 JP6404378B2 (ja) 2018-10-10

Family

ID=40210565

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010515276A Expired - Fee Related JP5529732B2 (ja) 2007-07-06 2008-07-03 前立腺癌における再発性遺伝子融合
JP2014016532A Expired - Fee Related JP6035634B2 (ja) 2007-07-06 2014-01-31 前立腺癌における再発性遺伝子融合
JP2015205414A Withdrawn JP2016019542A (ja) 2007-07-06 2015-10-19 前立腺癌における再発性遺伝子融合
JP2017023924A Expired - Fee Related JP6404378B2 (ja) 2007-07-06 2017-02-13 前立腺癌における再発性遺伝子融合

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2010515276A Expired - Fee Related JP5529732B2 (ja) 2007-07-06 2008-07-03 前立腺癌における再発性遺伝子融合
JP2014016532A Expired - Fee Related JP6035634B2 (ja) 2007-07-06 2014-01-31 前立腺癌における再発性遺伝子融合
JP2015205414A Withdrawn JP2016019542A (ja) 2007-07-06 2015-10-19 前立腺癌における再発性遺伝子融合

Country Status (6)

Country Link
EP (3) EP2167689B1 (enExample)
JP (4) JP5529732B2 (enExample)
AU (1) AU2008275304B2 (enExample)
CA (2) CA2814246A1 (enExample)
WO (1) WO2009009432A2 (enExample)
ZA (1) ZA201000128B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5512125B2 (ja) 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2008039774A1 (en) 2006-09-25 2008-04-03 Mayo Foundation For Medical Education And Research Extracellular and membrane-associated prostate cancer markers
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CA2814246A1 (en) * 2007-07-06 2009-01-15 The Regents Of The University Of Michigan Solute carrier family 45 member 3 (slc45a3) and erg family gene fusions in prostate cancer
ES2376509T3 (es) 2007-07-06 2012-03-14 The Regents Of The University Of Michigan Reordenamientos de genes mipol 1-etv1.
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
WO2011034906A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
JP6044935B2 (ja) 2013-03-11 2016-12-14 学校法人日本大学 新規ｐｉポリアミド
CN105308186A (zh) * 2013-03-15 2016-02-03 詹森药业有限公司 预测性生物标记的测定法
EP2975078A1 (en) 2014-08-14 2016-01-20 Omya International AG Surface-treated fillers for breathable films
JP6920683B2 (ja) 2015-10-08 2021-08-18 凸版印刷株式会社 ピロールイミダゾール含有ポリアミドを用いた標的二本鎖核酸分子の濃縮方法およびキット
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
AU2018310987A1 (en) 2017-08-04 2020-02-27 Decipher Biosciences, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
CN114634913A (zh) * 2022-02-27 2022-06-17 复旦大学 肿瘤硬脑膜转移模型的构建方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0232967B1 (en) 1986-01-10 1993-04-28 Amoco Corporation Competitive homogeneous assay
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US4968103A (en) 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5225326A (en) 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5480784A (en) 1989-07-11 1996-01-02 Gen-Probe Incorporated Nucleic acid sequence amplification methods
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
CA2148252C (en) 1992-10-30 2007-06-12 Roger Brent Interaction trap system for isolating novel proteins
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
AU6045094A (en) 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Drug composition containing nucleic acid copolymer
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
DK0787200T3 (da) 1994-10-28 2005-08-15 Univ Pennsylvania Forbedret adenovirus og fremgangsmåder til anvendelse heraf
JP3189000B2 (ja) 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US5872154A (en) 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
AU6261696A (en) 1995-06-05 1996-12-24 Trustees Of The University Of Pennsylvania, The A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6121489A (en) 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
WO1997033909A2 (en) 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
AU713667B2 (en) 1996-04-12 1999-12-09 Phri Properties, Inc. Detection probes, kits and assays
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
HUP0002095A3 (en) 1997-02-25 2002-02-28 Corixa Corp Seattle Compounds for immunotherapy of prostate cancer and methods for their use
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6198107B1 (en) 1997-03-07 2001-03-06 Clare Chemical Research, Inc. Fluorometric detection using visible light
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
AU7019498A (en) 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
WO1999002685A1 (en) 1997-07-11 1999-01-21 Introgene B.V. Interleukin-3 gene therapy for cancer
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
JP4646404B2 (ja) 1998-07-02 2011-03-09 ジェン−プローブ・インコーポレーテッド 分子トーチ（ｔｏｒｃｈ）
CA2340682A1 (en) 1998-08-14 2000-02-24 Aventis Pharmaceuticals Products Inc. Adenovirus formulations for gene therapy
KR20020013464A (ko) 1998-08-27 2002-02-20 추후제출 이종 유전자의 전달을 위한 표적화된 아데노바이러스 벡터
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6828429B1 (en) 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
EP1055734B1 (en) 1999-05-24 2004-10-13 Tosoh Corporation Method for assaying ribonucleic acid
WO2001098537A2 (en) 2000-06-17 2001-12-27 Third Wave Technologies, Inc. Nucleic acid accessible hybridization sites
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
JP4336198B2 (ja) 2001-09-06 2009-09-30 アトナーゲン アクチエンゲゼルシャフト 細胞の選択、および／または定性および／または定量検出のための方法および診断キット
JP2005517450A (ja) 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＲＮＡ干渉媒介性標的発見および標的評価
CA2524572C (en) 2003-05-01 2018-07-10 Gen-Probe Incorporated Oligonucleotides comprising a molecular switch having enhanced sensitivity to the presence of a mismatch
WO2005038054A1 (en) 2003-10-20 2005-04-28 Zicai Liang METHOD OF MEASURING THE EFFICACY OF siRNA MOLECULES
GB0327726D0 (en) 2003-11-28 2003-12-31 Isis Innovation Method
EP2071031B1 (en) 2004-08-27 2013-10-09 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
JP5512125B2 (ja) * 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
CA2814246A1 (en) * 2007-07-06 2009-01-15 The Regents Of The University Of Michigan Solute carrier family 45 member 3 (slc45a3) and erg family gene fusions in prostate cancer

Similar Documents

Publication Publication Date Title
JP5861244B2 (ja) 新規ｒｏｓ１融合体の検出法
JP2010508855A5 (enExample)
JP2010259438A5 (enExample)
JP2009507492A5 (enExample)
JP2010532663A5 (enExample)
JP2012526554A5 (enExample)
WO2011034906A4 (en) Recurrent gene fusions in prostate cancer
WO2014047285A1 (en) Identifying taxane sensitivity in prostate cancer patients
JP2015531590A5 (enExample)
WO2013141266A1 (ja) 新規ｒｅｔ融合体の検出法
JP2019023645A5 (enExample)
RU2016144177A (ru) Способы избирательного лечения астмы с использованием антагонистов il-13
JP6531312B2 (ja) Ｂｃｒ−ａｂｌ阻害剤耐性関連変異の検出方法及びこれを用いたｂｃｒ−ａｂｌ阻害剤耐性を予測するためのデータ取得方法
CN105543408B (zh) 冠心病早期诊断标志物
JP2008509673A5 (enExample)
CN102439174B (zh) 基于检测slc45a3-elk4融合转录子的用于诊断前列腺癌的组合物和方法
CN106795550A (zh) 与前列腺癌有关的基因组重排和使用所述基因组重排的方法
JP2013536442A5 (enExample)
CN105296659B (zh) 一种与缺血性脑卒中相关的基因标记物
JP2015524656A (ja) Ｃｄｋ阻害剤と関連するバイオマーカー
CN103937891B (zh) 一种检测白血病融合基因的多重pcr试剂盒
CN102234681A (zh) 一种检测基因融合的方法
JP2013503644A5 (enExample)
CN107043811B (zh) Cfap20基因在骨质疏松症诊断中的应用
JP2021503289A (ja) 新規なｃｉｐ２ａバリアント及びその使用